FDA Grants Avastin Safety Hearing For Genentech
The company said the FDA scheduled a hearing for June 28 and 29 to determine whether Avastin should remain approved for use, granting the company’s appeal of the FDA’s December downgrading of the drug.
“We appreciate the opportunity to continue our discussion with the FDA during...
Already a subscriber? Click here to login